Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 438,500 shares, a drop of 11.8% from the November 30th total of 497,300 shares. Based on an average daily volume of 93,300 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.8% of the company’s stock are short sold.

Aspira Women’s Health Price Performance

NASDAQ:AWH traded up $0.01 on Tuesday, hitting $0.71. 46,122 shares of the company’s stock were exchanged, compared to its average volume of 77,111. The company has a market cap of $11.90 million, a P/E ratio of -0.59 and a beta of 1.39. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65. The firm has a 50-day moving average price of $0.81 and a 200-day moving average price of $1.01.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently bought a new stake in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co acquired a new stake in Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Aspira Women’s Health in a report on Tuesday. They set a “hold” rating on the stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.